Publicaciones en colaboración con investigadores/as de Essen University Hospital (11)

2024

  1. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

    European Urology

  2. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 1026-1038

2022

  1. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

2020

  1. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology

  2. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

    European Urology, Vol. 77, Núm. 2, pp. 223-250

  3. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

    Cancer, Vol. 126, Núm. 18, pp. 4156-4167

2019

  1. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

    Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727

2018

  1. Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

    European Urology

2017

  1. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

    European Urology, Vol. 72, Núm. 6, pp. 962-971

2015

  1. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

    British Journal of Cancer, Vol. 113, Núm. 1, pp. 12-19

  2. Nivolumab versus everolimus in advanced renal-cell carcinoma

    New England Journal of Medicine, Vol. 373, Núm. 19, pp. 1803-1813